Yahoo Finance

Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 ...

NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today ...
Pharmabiz

Regeneron Pharma announces first clinical data for REGN5458 show positive preliminary ...

Regeneron Pharmaceuticals, a leading biotechnology company announced initial clinical data for REGN5458, a BCMAxCD3 bispecific antibody, in patients with relapsed or refractory (R/R) multiple myeloma.
Nasdaq

Tiziana Advances Phase 2 Site Selection for Its Lead Clinical Program in Non-Active ...

Tiziana Life Sciences Ltd. (NASDAQ: TLSA) recently announced the Company has initiated site selection for its lead intranasal anti-CD3 monoclonal antibody drug candidate “foralumab” program entering ...
CNN

Atreca and Xencor Enter Strategic Collaboration to Discover, Develop and Commercialize ...

SOUTH SAN FRANCISCO, Calif. and MONROVIA, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel ...